Viatris makes good on CEO's dealmaking promise with $25M licensing pact for Lexicon's heart med Inpefa

After Viatris’ CEO earlier this year promised to be “opportunistic” about future business development moves, the company is making good on that pledge with a new licensing pact to bolster its cardiovascular portfolio.